Navigation Links
ViaDerma, Inc. Announces Strategic Partnership With The Brewer Group
Date:8/5/2014

MINNEAPOLIS, and BEVERLY HILLS, Calif., Aug. 5, 2014 /PRNewswire/ -- ViaDerma, Inc. (OTCQB: VDRM), a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research and development, and The Brewer Group, Inc. (TBG), a diversified global investment advisory firm, today announced a new strategic partnership. TBG will expand ViaDerma's business development and marketing efforts at home and abroad to grow interest in ViaDerma's patent-pending pharmaceutical delivery system, which allows for rapid transdermal transfer of active ingredients and immediate relief of symptoms.

ViaDerma licenses products in fields of medicine ranging from infectious disease treatments to stem-cell therapy. Pharmaceutical companies seeking more efficient methods for delivering their products to patients will have new access to solutions worldwide, as The Brewer Group, Inc. and ViaDerma, Inc. leverage TBG's vast network to pave the way for new strategic business alliances and expand the range of the breakthrough rapid delivery of nutrients and medicines using ViaDerma's technology.

ViaDerma continues to develop new applications for its trade-secret Rapid Active Ingredient Delivery System (RAIDS), and founder Dr. Christopher Otiko emphasizes its extreme versatility. "The speed of the RAIDS method for pharmaceutical distribution and the wide variety of products that can utilize it will allow medical professionals and general consumers alike to benefit from faster treatment," Dr. Otiko said. "Products using RAIDS are at the forefront of medical sophistication and nearly any drug that medical professionals can administer as a pill can utilize RAIDS for quicker delivery, from pain relievers to cosmetics. As ViaDerma, Inc. expands, our partnership with The Brewer Group will combine their experience and network with our revolutionary technologies to reach ever-larger audiences."

Using tailored business development strategies including exclusive access to its extensive network and established relationships spanning the globe, TBG will reach out to synergetic companies and partner organizations, explore licensing opportunities as well as provide ongoing marketing support and enhance global exposure for ViaDerma's unique technology.

"I'm excited to be working with an organization like ViaDerma, because their technology represents a fundamental shift in the way we should expect treatment to progress," The Brewer Group CEO H.E. Ambassador Jack Brewer said. "What if patients saw results from antibiotics after just a day of treatment, instead of a week? People would come to demand that kind of speed, and TBG is ready to connect ViaDerma Inc. with strategic partners to meet those expectations."

About ViaDerma, Inc.

ViaDerma, Inc. is a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research and development. ViaDerma licenses products in the fields of medicine ranging from infectious diseases to stem-cell therapy. Dr. Christopher Otiko is the company's founder, and ViaDerma became a publicly-traded company in 2014. For more information, go to www.viadermalicensing.com.

About The Brewer Group, Inc.

The Brewer Group (TBG) is a multi-faceted global investment advisory firm focused on providing tailored services including capital markets, asset management, specialty finance and business development for public and private companies as well as high-profile clientele. TBG leverages its relationships with key international decision-makers spanning government agencies, private equity firms, corporations, NPOs, leaders in government, and sports and entertainment to place TBG in a unique position to execute a wide range of services around the globe. For further information, please visit www.thebrewergroup.com.

 


'/>"/>
SOURCE ViaDerma, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
3. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
4. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
5. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
6. WuXi PharmaTech Announces Third-Quarter 2011 Results
7. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
8. Spherix Announces Third Quarter Financial Results
9. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
10. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
11. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... , Jan. 24, 2017  Asterias Biotherapeutics, Inc. ... field of regenerative medicine, today announced positive efficacy ... clinical trial that showed additional motor function improvement ... million AST-OPC1 cells in AIS-A patients with complete ... of upper extremity motor function is critically important ...
(Date:1/24/2017)... Switerland (PRWEB) , ... January 24, 2017 , ... ... first commercially available malaria Plasmodium falciparum culture panels with standard concentrations of histidine ... which are available in a range of concentrations from six different malaria strains, ...
(Date:1/24/2017)... , ... January 23, 2017 , ... Oklahoma City based ... newest client for the firm’s PERFEQTA software and legacy product QC Manager 2.0. ... the dynamic team at CJBC and thrilled that they have decided to implement PERFEQTA ...
(Date:1/24/2017)... , Jan. 23, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: ... into an underwriting agreement with Rodman & Renshaw, a ... as sole book running manager and representative of several underwriters, ... a firm commitment basis a minimum of 2,105,264 shares ... to purchase a minimum of 1,052,632 shares of common ...
Breaking Biology Technology:
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
(Date:1/12/2017)... Jan. 12, 2017  New research undertaken by Fit ... the future.  1,000 participants were simply asked which office technology ... we may consider standard issue.  Insights on what will ... also gathered from futurists and industry leaders including Penelope ... Canton .  Some of these findings ...
(Date:1/6/2017)... LA JOLLA, Calif. , Jan. 6, 2017 ... Phase 1 safety studies in healthy volunteers of ... CM4620, intended to treat acute pancreatitis. ... pancreas, is typically a mild disorder, but can ... to organ failure and sepsis, where extended hospital ...
Breaking Biology News(10 mins):